Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

BACKGROUND: Ulixertinib is a novel oral ERK inhibitor that has shown promising single-agent activity in a phase I clinical trial that included patients with RAS-mutant cancers. METHODS: We conducted a phase Ib trial combining ulixertinib with gemcitabine and nab-paclitaxel (GnP) for untreated metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Grierson, Patrick M, Tan, Benjamin, Pedersen, Katrina S, Park, Haeseong, Suresh, Rama, Amin, Manik A, Trikalinos, Nikolaos A, Knoerzer, Deborah, Kreider, Brent, Reddy, Anupama, Liu, Jingxia, Der, Channing J, Wang-Gillam, Andrea, Lim, Kian-Huat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907047/
https://www.ncbi.nlm.nih.gov/pubmed/36427020
http://dx.doi.org/10.1093/oncolo/oyac237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907047/
https://www.ncbi.nlm.nih.gov/pubmed/36427020
http://dx.doi.org/10.1093/oncolo/oyac237

Ejemplares similares